Video Lectures from Keane's Corner

HERO Trial: Oral Relugolix for ADT in Advanced Prostate Cancer - Thomas Keane

Personalized Therapy with Erdafitinib: A Biomarker-Targeted Therapy for Urothelial Cancer - Arlene Siefker-Radtke

PROfound: Olaparib for Metastatic Castrate Resistant Prostate Cancer - Thomas Keane

AUA 2020 Review: Genomic Heterogeneity in Tissue-Based Prognostic Signatures from Prostate Biopsies: The Results From Two Prospective Trials - Thomas Keane

AUA 2020 Review: Using Biomarkers in Patients with a Positive Multiparametric MRI: 4Kscore Predicts Presence of Cancer Outside the Index Lesion - Thomas Keane

Developments in Imaging Prior to Biopsy — Are Systematic Biopsies Still Required - Tom Keane

KEYNOTE-057 in High-Risk, Non-Muscle Invasive Bladder Cancer: Trial Highlights by Tom Keane

Effectiveness of Radical Prostatectomy with Adjuvant Radiotherapy versus Radiotherapy Plus ADT for Men with Advanced Prostate Cancer - Tom Keane

CARMENA in mRCC and Surgical Management Cases in Bladder Cancer from ASCO 2018 - Tom Keane

Prostate Cancer Highlights from AUA 2018 with Tom Keane

The Changing Landscape in Advanced Bladder Cancer - Tom Keane

New Concepts in ADT- Thomas Keane

Discussion of an Online Tool to Explore Evolving Practice Patterns in Renal Cell Carcinoma - Thomas Keane

Discussion of the IMmotion 151 Trial: Atezolizumab Plus Bevacizumab vs Sunitinib in Untreated Metastatic Renal Cell Carcinoma - Thomas Keane

Discussion of the CABOSUN trial - Advanced Renal Cell Carcinoma - Thomas Keane

Discussion on FALCON: Impact of 18F-fluciclovine PET/CT on Clinical Management Choices for Men with Biochemically Recurrent Prostate Cancer

Discussion on SPARTAN: A Study of Apalutamide in Men with Non-Metastatic Castration-resistant Prostate Cancer - Thomas Keane

News Update: Apalutamide as a Treatment for Non-Metastatic Castration-Resistant Prostate Cancer - Thomas Keane